Rezolute, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| RZLT | RLMD | KROS | SLDB | NKTR | RIGL | |
|---|---|---|---|---|---|---|
| Market cap | 383.02M | 444.81M | 214.73M | 699.11M | 1.31B | 958.09M |
| P/E (TTM) | — | — | — | — | — | 3.0 |
| Forward P/E | -8.5 | -10.2 | -1.6 | -3.8 | -3.7 | 10.4 |
| Price/book | 3.8 | 2.2 | 0.8 | 2.9 | 1.5 | 2.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −57.11% | +70.12% | −30.80% | +54.69% | −30.19% | +42.00% |
| Today | −1.25% | −2.34% | 0.00% | +3.82% | +1.91% | +4.97% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All RZLT news ›Analysts’ Top Healthcare Picks: Verastem (VSTM), Rezolute (RZLT)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Verastem (VSTM), Rezolute (RZLT) and Rhythm Pharmaceuticals (RYTM) with bullish sentiments. In a report released yesterday, Jeet Mukherjee from…
Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Nasdaq Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism Oct 14, 2026 4:05pm EDT Topline results expected mid-December 2026 REDWOOD CIT
Rezolute, Inc. (NASDAQ:RZLT) Stock Now Rated “Moderate Buy” by Sell-Side Analysts
Read Our Latest Analysis on Rezolute Rezolute (NASDAQ:RZLT – Get Free Report) last released its quarterly earnings data on Thursday, September 24th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of…
Rezolute upgraded at Cantor on pre-BLA meeting for ersodetug
Cantor Fitzgerald upgrades Rezolute as FDA signals ersodetug congenital hyperinsulinism data is sufficient for a filing. Read more here. - Cantor Fitzgerald upgraded Rezolute (RZLT) to overweight from neutral as it sees the US FDA…
Rezolute says FDA recommends pre‑BLA meeting after congenital HI trial miss
Agency feedback follows a Phase 3 miss in congenital hyperinsulinism; Rezolute will weigh its filing strategy after tumor HI data. A request for a pre-BLA meeting is the next regulatory step for Rezolute, Inc. NASDAQRZLT after it said on…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- defenseworld.net1
- markets.businessinsider.com1
- mugglehead.com1
- nasdaq.com1
- seekingalpha.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.